WO2000049137B1 - Pluripotential cell derived from an embryonic stem cell and a nucleus of a somatic cell - Google Patents

Pluripotential cell derived from an embryonic stem cell and a nucleus of a somatic cell

Info

Publication number
WO2000049137B1
WO2000049137B1 PCT/GB2000/000576 GB0000576W WO0049137B1 WO 2000049137 B1 WO2000049137 B1 WO 2000049137B1 GB 0000576 W GB0000576 W GB 0000576W WO 0049137 B1 WO0049137 B1 WO 0049137B1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
pluripotential
embryonal
tissue
cell according
Prior art date
Application number
PCT/GB2000/000576
Other languages
French (fr)
Other versions
WO2000049137A3 (en
WO2000049137A2 (en
Inventor
Peter Andrews
Paul Kemp
Original Assignee
Intercytex Ltd
Peter Andrews
Paul Kemp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercytex Ltd, Peter Andrews, Paul Kemp filed Critical Intercytex Ltd
Priority to CA002371900A priority Critical patent/CA2371900A1/en
Priority to AU25636/00A priority patent/AU2563600A/en
Priority to JP2000599863A priority patent/JP2003514509A/en
Priority to EP00903886A priority patent/EP1153123A2/en
Publication of WO2000049137A2 publication Critical patent/WO2000049137A2/en
Publication of WO2000049137A3 publication Critical patent/WO2000049137A3/en
Publication of WO2000049137B1 publication Critical patent/WO2000049137B1/en
Priority to HK02102269.8A priority patent/HK1040741A1/en
Priority to HK02102672.9A priority patent/HK1042112A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/04—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from germ cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)

Abstract

The invention relates to isolated pluripotential cells, comprising at least part of the cytoplasm derived from an embryonic stem cell/embryonic germ cell and a nucleus of a somatic cell. The invention also relates to methods to prepare such cell and therapeutic composition comprising said cells.

Claims

AMENDED CLAIMS[received by the International Bureau on 04 December 2000 (04.12.00); original claims 1 -29 replaced by amended claims 1 -25 (5 pages)]
1. A cell, which cell is diploid and possesses at least one pluripotential characteristic, which characteristic includes the ability to differentiate into at least one selected tissue type, and which cell comprises at least part of the cytoplasm derived from a mammalian embryonal stem cell or mammalian embryonal germ cell combined with a nucleus of a mammalian somatic cell.
2. A cell according to Claim 1 characterised in that said pluripotential characteristic includes the ability of said cell to proliferate in culture in an undifferentiated state .
3. A cell according to Claim 2 characterised in that said cell has the capacity to proliferate in continuous culture in an undifferentiated state for at least six months and ideally 12 months.
4. A cell according to any of Claims 1-3 characterised in that said pluripotential characteristic includes the expression of at least one selected marker of pluripotential cells.
5. A cell according to Claim 4 characterised in that said selected marker is expression of Oct4.
6. A cell according to Claim 4 characterised in that said selected marker is a cell surface marker. 47
7. A cell according to Claim 6 characterised m that said cell surface marker is selected from the group including: SSEA-1 (-); and/or SSEA-3 (+) , and/or SSEA-4 (+) , and/or TRA-1-60 (+) ; and/or TRA-1-81 (+) ; and/or alkaline phosphatase (+) .
8. A cell according to Claims 1-7 characterised in that said pluripotential characteristic includes the presence of telomerase activity m said pluripotential cell.
9. A cell according to any of Claims 1-8 characterised m that said pluripotential characteristic includes the presence of a chromosomal methylation pattern characteristic of pluripotential cells.
10. A cell according to any of Claim 1-9 characterised m that said pluripotential characteristic includes the ability to induce tumours when introduced into an animal.
11. A cell-line comprising cells according to any of Claims 1-10.
12. A cell-line according to Claim 11 characterised in that said cell-line is of human origin.
13. A method for preparing a cell according to any of
Claims 1-10 or a cell-line according to Claims 11 or 12 comprising :
(l) combining at least one embryonal stem/embryonal germ cell with at least one somatic cell, 48
(ii) removing from said combined cell, the embryonal stem/embryonal germ cell nucleus; (iii) culturing said cell under conditions conductive to proliferation and expansion of said cell; and, optionally (iv) storing said cell culture under suitable storage conditions.
14. A method for preparing a cell according to any of Claims 1-10 or a cell-line according to Claim 11 or 12 comprising;
(i) providing at least one embryonal stem/embryonal germ cell;
(ii) separating at least part of the cytoplasm from the nucleus of said embryonal stem/embryonal germ cell; (iii) isolating said cytoplasmic part (iv) combining said cytoplasmic part with at least one somatic cell; (v) growing said combined cell in culture; and optionally (vi) storing said combined cell under suitable storage conditions.
15. A method according to Claim 14 characterised in that said cytoplasmic part is provided as a cytoplast.
16. A method according to Claim 15 characterised in that said cytoplast is combined with said somatic cell via cytoplast/somatic cell fusion.
17. A method according to Claims 13-16 characterised in 49
that said embryonal stem/embryonal germ cell and somatic cell are of human origin.
18. A cell culture comprising at least one cell according to any of Claims 1-10.
19. A method for inducing differentiation of at least one cell according to any of Claims 1-10 comprising;
(i) providing a cell according to any of Claims
1-10; (ii) culturing said cell under conditions conductive to the differentiation of said cell into at least one tissue; and optionally (iii) storing of said differentiated tissue prior to use under suitable storage conditions.
20. A method of Claim 19 characterised in that said method provides a tissue type selected from at least one of the following; neural, smooth muscle, striated muscle, cardiac muscle, bone, cartilage, liver, kidney, respiratory epithelum haematopopietic cells, spleen, skin, stomach, intestine.
21. At least one tissue type or organ comprising at least one cell according to any of Claims 1-10.
22. A therapeutic composition comprising at least one cell according to any of Claims 1-10 including a suitable excipient, diluant or carrier.
23. A therapeutic composition according to Claim 22 50
characterised in that said therapeutic composition provided for use in tissue transplantation.
24. A method to treat conditions or diseases requiring transplantation of tissue comprising:
(i) providing at least one tissue type or organ according to Claim 22 or 23; (ii) surgically introducing said tissue or organ into a patient to be treated; and (iii) treating said patient under conditions which are conductive to the acceptance of said transplanted tissue by said patient.
25. A kit comprising at least one cell according to any of Claims 1-10; instructions with respect to maintenance of said cell in culture; and, optionally, factors required to induce differentiation of said cell to at least one desired tissue type or organ.
PCT/GB2000/000576 1999-02-20 2000-02-18 Pluripotential cell derived from an embryonic stem cell and a nucleus of a somatic cell WO2000049137A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002371900A CA2371900A1 (en) 1999-02-20 2000-02-18 Pluripotential cell derived from an embryonic stem cell and a nucleus of a somatic cell
AU25636/00A AU2563600A (en) 1999-02-20 2000-02-18 Pluripotential cells-2
JP2000599863A JP2003514509A (en) 1999-02-20 2000-02-18 Pluripotent functional cells-2
EP00903886A EP1153123A2 (en) 1999-02-20 2000-02-18 Pluripotential cells-2
HK02102269.8A HK1040741A1 (en) 1999-02-20 2002-03-26 Pluripotential cells-2
HK02102672.9A HK1042112A1 (en) 1999-02-20 2002-04-10 Pluripotential cells-2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903804.4A GB9903804D0 (en) 1999-02-20 1999-02-20 Pluripotential cells-2
GB9903804.4 1999-02-20

Publications (3)

Publication Number Publication Date
WO2000049137A2 WO2000049137A2 (en) 2000-08-24
WO2000049137A3 WO2000049137A3 (en) 2001-03-08
WO2000049137B1 true WO2000049137B1 (en) 2001-05-17

Family

ID=10848084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/000576 WO2000049137A2 (en) 1999-02-20 2000-02-18 Pluripotential cell derived from an embryonic stem cell and a nucleus of a somatic cell

Country Status (7)

Country Link
EP (1) EP1153123A2 (en)
JP (1) JP2003514509A (en)
AU (1) AU2563600A (en)
CA (1) CA2371900A1 (en)
GB (1) GB9903804D0 (en)
HK (2) HK1040741A1 (en)
WO (1) WO2000049137A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072343A1 (en) * 2000-11-09 2004-04-15 Verma Paul John Cell reprogramming
CA2461185A1 (en) * 2001-09-21 2003-04-03 Japan Science And Technology Corporation Method of screening reprogramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs
JP2004248505A (en) * 2001-09-21 2004-09-09 Norio Nakatsuji Undifferentiated fusion cell of somatic cell derived from es cell deficient in part or all of transplantation antigen and method for producing the same
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
MXPA06007252A (en) 2003-12-23 2007-01-23 Cythera Inc Definitive endoderm.
US9115342B2 (en) 2006-01-31 2015-08-25 Daiichi Sankyo Company Method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses
CA2650685C (en) 2006-04-28 2014-02-04 Asubio Pharma Co., Ltd. Method for inducing differentiation of pluripotent stem cells into cardiomyocytes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9517780D0 (en) * 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation

Also Published As

Publication number Publication date
GB9903804D0 (en) 1999-04-14
WO2000049137A3 (en) 2001-03-08
HK1042112A1 (en) 2002-08-02
JP2003514509A (en) 2003-04-22
HK1040741A1 (en) 2002-06-21
CA2371900A1 (en) 2000-08-24
AU2563600A (en) 2000-09-04
WO2000049137A2 (en) 2000-08-24
EP1153123A2 (en) 2001-11-14

Similar Documents

Publication Publication Date Title
DE69837270T2 (en) CORE TRANSFER WITH DIFFERENTIAL SOLIDS AND ADULTS DISPENSING CELLS
RU2322497C2 (en) Isolated homozygous stem cell (variants), method for its preparing (variants), method for preparing required cell-ancestor, differentiated cell, group of differentiated cells or tissue type
Polak et al. Stem cells and tissue engineering: past, present, and future
NZ334016A (en) Embryonic stem cell lines produced by cross species nuclear transplantation
EP2368974A1 (en) Methods for isolating mesenchymal stem cells from embryos of human or animals and extracting secretion substances thereof
WO2003014313A3 (en) Alternative compositions and methods for the culture of stem cells
US20040241838A1 (en) Stem cells
JP2003512052A5 (en)
JP2003514516A (en) Gynogenetic or orogenic development of pluripotent cells and cell lines and their use for producing differentiated cells and tissues
US5032407A (en) Gene transfer using transformed, neodetermined, embryonic cells
WO2002024873A1 (en) Stem cell therapy
WO2000049137B1 (en) Pluripotential cell derived from an embryonic stem cell and a nucleus of a somatic cell
HK1023599A1 (en) Cells for preventing graft rejection in transplantation and their uses.
AU2006227752A1 (en) Skin substitutes with improved purity
WO2000012682A1 (en) Primate embryonic stem cells with compatible histocompatibility genes
Bongso et al. The growth of inner cell mass cells from human blastocysts
JP2005523685A (en) Somatic embryonic stem cells and their differentiated progeny
WO2003083088A2 (en) Stem cell therapy
WO2002063938A3 (en) Production and use of dopaminergic cells to treat dopaminergic deficiencies
AU2564100A (en) Pluripotential cells-1
WO2023129418A1 (en) Nonhuman stem cells and their use for production of cultured meat
Papadaki Cardiac muscle tissue engineering
Pathak et al. Assessment of different stages of parthenogenetic embryos for production of embryonic stem cell like colonies
Rao Alternatives to embryonic stem cells and cloning: a brief scientific overview
MXPA01002174A (en) Primate embryonic stem cells with compatible histocompatibility genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: 2000903886

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 25636/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2371900

Country of ref document: CA

Ref country code: CA

Ref document number: 2371900

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 599863

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000903886

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09913854

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000903886

Country of ref document: EP